Synergistic Pre-Clinical Activity of Targeted Inhibition of KDM1A and BET Proteins Against Human AML Blast Progenitor Cells

被引：4
|
作者：
Fiskus, Warren [1 ]
Mill, Christopher Peter [1 ]
Soldi, Raffaella [2 ]
Han, Roulan [2 ]
Saenz, Dyana T. [1 ]
Nowak, Agnieszka J. [1 ]
Sun, Baohua [1 ]
Saenz, David N. [1 ]
DiNardo, Courtney D. [1 ]
Borthakur, Gautam [3 ]
Kadia, Tapan M. [3 ]
Jin, Wendy [1 ]
Ganesh, Thurika [4 ]
Rao, Vaishnavi [1 ]
Khoury, Joseph David [5 ]
Sharma, Sunil [6 ]
Bhalla, Kapil N. [3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Beta Cat Pharma, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[6] Huntsman Canc Inst, Salt Lake City, UT USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-114198
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3930
引用
收藏
页数：2
相关论文
共 19 条
  • [1] Targeted inhibition of KDM1A and BET proteins or DNMT1 exerts synergistic lethal activity against human AML blast progenitor cells
    Fiskus, Warren C.
    Mill, Christopher P.
    Saenz, Dyana T.
    Nowak, Agnieszka J.
    Sun, Baohua
    Saenz, David N.
    Kornblau, Steven M.
    Sharma, Sunil
    Bhalla, Kapil N.
    CANCER RESEARCH, 2018, 78 (13)
  • [2] Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells
    Fiskus, Warren
    Mill, Christopher Peter
    Karkhanis, Vrajesh
    Lara, Bernardo H.
    Bose, Prithviraj
    Masarova, Lucia
    Kadia, Tapan M.
    Shao, Nancy
    Bhalla, Isean
    Maher, James V.
    Khoury, Joseph D.
    Sharma, Sunil
    Manshouri, Taghi
    Verstovsek, Srdan
    Bhalla, Kapil N.
    BLOOD, 2019, 134
  • [3] Pre-Clinical Efficacy of Co-Targeting GFI1/KDM1A and BRD4 or JAK1/2 Against AML and Post-MPN Secondary AML Blast Progenitor Cells
    Fiskus, Warren
    Mill, Christopher Peter
    Birdwell, Christine
    Lara, Bernardo H.
    Bose, Prithviraj
    Masarova, Lucia
    Kadia, Tapan M.
    Khoury, Joseph D.
    Manshouri, Taghi
    Verstovsek, Srdan
    Bhalla, Kapil N.
    BLOOD, 2020, 136
  • [4] Pre-Clinical Efficacy of Combined Therapy with LSD1 Antagonist SP-2509 and Pan-Histone Deacetylase Inhibitor Against AML Blast Progenitor Cells
    Fiskus, Warren
    Sharma, Sunil
    Abhyankar, Sunil
    McGuirk, Joseph
    Bearss, David J.
    Bhalla, Kapil
    BLOOD, 2012, 120 (21)
  • [5] Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
    W Fiskus
    S Sharma
    B Shah
    B P Portier
    S G T Devaraj
    K Liu
    S P Iyer
    D Bearss
    K N Bhalla
    Leukemia, 2014, 28 : 2155 - 2164
  • [6] Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
    Fiskus, W.
    Sharma, S.
    Shah, B.
    Portier, B. P.
    Devaraj, S. G. T.
    Liu, K.
    Iyer, S. P.
    Bearss, D.
    Bhalla, K. N.
    LEUKEMIA, 2014, 28 (11) : 2155 - 2164
  • [7] Pre-Clinical Efficacy of Combined Therapy with Novel β-Catenin Antagonist BC2059 and Histone Deacetylase Inhibitor Against Cultured and Primary AML Blast Progenitor Cells
    Bhalla, Kapil
    Fiskus, Warren
    Horrigan, Stephen K.
    Abhyankar, Sunil
    McGuirk, Joseph
    Sharma, Sunil
    BLOOD, 2012, 120 (21)
  • [8] Erratum: Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
    W Fiskus
    S Sharma
    B Shah
    B P Portier
    S G T Devaraj
    K Liu
    S P Iyer
    D Bearss
    K N Bhalla
    Leukemia, 2017, 31 : 1658 - 1658
  • [9] BET Protein Bromodomain Antagonist-Based Combinations Exert Synergistic Pre-Clinical Activity Against Ibrutinib-Sensitive or -Resistant Human Mantle Cell Lymphoma (MCL) Cells
    Sun, Baohua
    Fiskus, Warren
    Saenz, Dyana T.
    Krieger, Stephanie
    Zhang, Liang
    Parmar, Simrit
    Wang, Michael
    Bhalla, Kapil N.
    BLOOD, 2015, 126 (23)
  • [10] Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells
    Warren Fiskus
    Tianyu Cai
    Courtney D. DiNardo
    Steven M. Kornblau
    Gautam Borthakur
    Tapan M. Kadia
    Naveen Pemmaraju
    Prithviraj Bose
    Lucia Masarova
    Kimal Rajapakshe
    Dimuthu Perera
    Cristian Coarfa
    Christopher P. Mill
    Dyana T. Saenz
    David N. Saenz
    Baohua Sun
    Joseph D. Khoury
    Yu Shen
    Marina Konopleva
    Kapil N. Bhalla
    Blood Cancer Journal, 9
12